Navigation Links
ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease
Date:12/7/2009

ract in a process that ultimately results in the persistent inflammation underlying IBD. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn's disease and other inflammatory disorders of the GI system.

"Current approaches to the treatment of Crohn's disease often result in serious side effects, especially following long-term use of these drugs," said Pirow Bekker, M.D., Ph.D., Senior Vice President, Medical and Clinical Affairs of ChemoCentryx. "These results suggest that Traficet-EN has the potential to keep Crohn's patients in remission without complications such as broad immunosuppression associated with current therapies."

"Data generated from these two studies are groundbreaking in nature and have the potential to revolutionize the way Crohn's disease and ulcerative colitis are treated," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "We are particularly pleased that we have for the first time definitively identified the CCR9 chemokine ligand in the large bowel which will broaden the scope of digestive tract disorders that Traficet-EN could potentially treat successfully."

Results for PROTECT-1 Maintenance Period of Study

Over the course of the Maintenance period, the remission rate in the Traficet-EN group remained between 47% and 50%, whereas the remission rate continued to decrease in the placebo group. At week 36, 47% of subjects in the Traficet-EN group were in remission compared to 31% in the placebo group (p=0.01). Furthermore, at week 36, 41% of patients in the Traficet-EN group were in corticosteroid-free remission compared to 28% in the placebo group (p=0.04).

Study Design for PROTECT-1 Trial

The randomized, placebo-controlled, double-blind clinical trial of 436 patients is comprised of three discrete periods which allows for evaluation of efficacy and safety of Traficet-EN in inducing a cl
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
2. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
3. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
4. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
7. Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution
8. Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
9. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
10. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
11. Pharmasset Reports Fiscal Year End 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... ALEXANDRIA, Va. and WASHINGTON ... of Specialty Pharmacy (NASP) and SmartBrief recently partnered to ... with a snapshot of the top news in the ... specialty pharmacies, pharmaceutical and biotechnology manufacturers, GPOs, distributors and ... free resource will launch on April 27, 2015. ...
(Date:4/27/2015)... -- The North America ... $4,211.2 million by 2019, at a CAGR of 5.0% from ... the North America ophthalmology surgery device ... It also provides a glimpse of the segmentation of this ... tables and figures. http://www.micromarketmonitor.com/market/north-america-ophthalmology-surgery-devices-9102894245.html ...
(Date:4/27/2015)... The North America ... and geography and includes analysis and forecast of revenue. This ... expected to reach $829.9 million by 2019, at a CAGR ... the TOC of the North America Optical microscopy market report, ... also provides a glimpse of the segmentation in this market, ...
Breaking Medicine Technology:NASP and SmartBrief Partner on Specialty Pharmacy SmartBrief 2North America Ophthalmology Surgery Device Market is Expected to Reach $4,211.2 Million by 2019, at a CAGR of 5.0% From 2014 to 2019 2North America Ophthalmology Surgery Device Market is Expected to Reach $4,211.2 Million by 2019, at a CAGR of 5.0% From 2014 to 2019 3North America Optical Microscopy Market is Expected to Reach $829.9 Million by 2019, at a CAGR of 3.0% From 2014 to 2019 2North America Optical Microscopy Market is Expected to Reach $829.9 Million by 2019, at a CAGR of 3.0% From 2014 to 2019 3
... Necessary For Diabetic Patients, BOSTON, Sept. 13 ... the United States alone. Coronary artery,disease (CAD) is a ... ischemia is common, and cardiac death or myocardial,infarction may ... the Detection of Ischemia in Asymptomatic Diabetics (DIAD),Study, presented ...
... Australia, Sept. 12 Sunshine Heart (ASX: SHC),a ... assist,technologies, today announced that it has received conditional ... U.S. Food and Drug,Administration (FDA) to begin its ... in patients with moderate heart failure. C-Pulse is,an ...
Cached Medicine Technology:Screening for Ischemia in Asymptomatic Patients With Type 2 Diabetes: Five- Year Outcomes in the DIAD Study 2Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial 2Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial 3
(Date:4/28/2015)... Colorado spine surgeon Donald Corenman, MD, ... popular spine education website NECKANDBACK.COM and his ... Media. This website has been redesigned to help patients ... spine, causes of neck and back pain, and conditions ... and personally answers questions in the neck and back ...
(Date:4/28/2015)... The buyer power score for ... indicating a medium level of buyer power in the ... equal power during negotiations. One factor helping buyer power ... health insurance policy from an insurance carrier (such as ... choose to self-fund their own policy or forgo insurance ...
(Date:4/28/2015)... It’s not all about the law at the Law ... litigation and plaintiff’s personal injury lawyer that has also served ... also about giving back to the community. This is ... Research Center Innovator’s Network. , “I believe there is a ... can and do good community-focused work in their communities,” said ...
(Date:4/28/2015)... SeniorCare.com has published the Misconception ... problem Americans have regarding aging and long-term care needs. ... services as they age, 63% of Americans do NOT ... the report, Carol Marak of SeniorCare.com interviewed 44 senior ... Care Association and The Scan Foundation. The experts discuss ...
(Date:4/28/2015)... Dead or damaged trees can quickly turn into ... cases, tree removal by a skilled team is recommended as ... , In their latest article , Precision Tree ... property owners today. Each method requires skill and expertise that ... , The article states that, “Tree removal is not “one ...
Breaking Medicine News(10 mins):Health News:Colorado Spine Surgeon Donald Corenman, MD, DC Launches Updated Version of NECKANDBACK.COM and Popular Back Pain Forum ASKSPINEDOC.COM 2Health News:Colorado Spine Surgeon Donald Corenman, MD, DC Launches Updated Version of NECKANDBACK.COM and Popular Back Pain Forum ASKSPINEDOC.COM 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 2Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 4Health News:Seattle Attorney Paul Schneiderman Helping to Combat Cancer 2Health News:SeniorCare.com Report: America Has a Major Misconception on Aging 2Health News:Tree Removal Methods and Services Discussed in Recent Article by Precision Tree Services 2
... Jan. 28 Prime Companies, Inc. (Pink Sheets: PCIR) ... that will allow it to spin off its wholly ... 2007, to a San Diego firm which, once it ... 15 percent of the new company.The agreement with TransPacific ...
... Essential Hospital Guide to Get Your Loved One Out Alive," by ... Health Book of the Year by Allbooks Review Editor,s Choice Awards ... ... 2009 -- "Critical Conditions: The Essential Hospital Guide to Get Your ...
... of Health Strategies & Solutions, Inc the largest healthcare consultant in ... her expertise in management, governance, finance, operations and medical staff. ... ... The nation,s leading healthcare consulting firm, Health Strategies & ...
... A University of Rochester Medical Center study challenges common assumptions ... some people, surprisingly high levels remain in the body even ... suggests that BPA exposure may come from non-food sources, or ... journal Environmental Health Perspectives published the research online ...
... Jan. 27 Minnesotans with chronic,conditions and disabilities ... under the proposed budget of Gov. Tim Pawlenty, ... Center. , "As a ... thousands of Minnesotans following an illness, surgery or ...
... officials say company distributed ,adulterated, peanut butter products in ... -- The Georgia facility that produced the peanut butter ... in the past distributed questionable peanut butter product, U.S. ... 2008, Peanut Corporation of America, which owns the now-closed ...
Cached Medicine News:Health News:Prime Companies Reaches Agreement to Spin Off Subsidiary; Shareholders Gain 15 Percent Stake in New Telecommunications Company 2Health News:"Critical Conditions" Wins Best Health Book of the Year Awards 2Health News:New Employee of the Nations Largest Healthcare Consulting Firm 2Health News:Rochester study raises new questions about controversial plastics chemical 2Health News:Rochester study raises new questions about controversial plastics chemical 3Health News:Courage Center Experts Disagree With Gov. Pawlenty's Proposed Budget Cuts 2Health News:Courage Center Experts Disagree With Gov. Pawlenty's Proposed Budget Cuts 3Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 2Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 3
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
VascoStim 2F are bipolar temporary pacing leads to be used in conjunction with thermodilution catheters with implemented paceport-channel....
Unipolar Ventricular Lead...
The Guidant Fineline leads are bipolar endocardial and designed for permanent implantation with pulse generators for cardiac pacing....
Medicine Products: